menu

Improving Severe Asthma Outcomes: A New Era in Identification and Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Severe Asthma Outcomes: A New Era in Identification and Management

close
0.50 credits
30 minutes
Improving Severe Asthma Outcomes: A New Era in Identification and Management
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Severe asthma is linked to significant morbidity, health care resource utilization, and long-term sequelae including airway remodeling and a greater risk of developing chronic obstructive pulmonary disease. These consequences emphasize the importance of improved identification and management of patients with severe asthma. Treatment guidelines may be confusing and it may be challenging to keep abreast of new developments. Routine assessments of lung function, frequency and severity of exacerbations, symptom control, and medication adherence are pivotal to provide necessary information for identifying and determining the most appropriate management strategy. An increased understanding of asthma pathophysiology and its correlation to disease activity has identified therapeutic targets. Biologic therapies that target T2 pathways and new supportive digital health technologies mark a new era in asthma management and treatment.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty have reported real or apparent conflicts of interest that have been resolved:

    Barbara P. Yawn, MD has disclosed the following relevant financial relationships:
    Advisory Group Member: AstraZeneca
    Advisory Board Member: Teva

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: Sanofi
    Consultant and Advisory Board Member: GlaxoSmithKline 

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for physicians and other health care professionals who manage patients with severe asthma. 

  • Learning Objectives

    • Distinguish between asthma control and asthma severity to identify patients with severe asthma based on an understanding of epidemiologic data and ongoing evaluations of symptoms, potential disease phenotypes, and treatment history;
    • Assess the clinical data of newer and emerging cytokine-targeting biologic medications in the treatment of severe asthma;
    • Recognize the benefits of facilitating communication with patients and their caregivers and coordinating with specialists to personalize therapy for patients with severe asthma.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Method of Participation and Receipt of Credit
    In order to receive credit, participants should watch the entire video. Upon completion of the video, please continue to the post-test and evaluation. A passing score of 70% on the post-test is required to receive credit. There is no fee for this activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This program is supported by an educational grant from Genentech, Inc. and AstraZeneca.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Severe asthma is linked to significant morbidity, health care resource utilization, and long-term sequelae including airway remodeling and a greater risk of developing chronic obstructive pulmonary disease. These consequences emphasize the importance of improved identification and management of patients with severe asthma. Treatment guidelines may be confusing and it may be challenging to keep abreast of new developments. Routine assessments of lung function, frequency and severity of exacerbations, symptom control, and medication adherence are pivotal to provide necessary information for identifying and determining the most appropriate management strategy. An increased understanding of asthma pathophysiology and its correlation to disease activity has identified therapeutic targets. Biologic therapies that target T2 pathways and new supportive digital health technologies mark a new era in asthma management and treatment.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty have reported real or apparent conflicts of interest that have been resolved:

    Barbara P. Yawn, MD has disclosed the following relevant financial relationships:
    Advisory Group Member: AstraZeneca
    Advisory Board Member: Teva

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: Sanofi
    Consultant and Advisory Board Member: GlaxoSmithKline 

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for physicians and other health care professionals who manage patients with severe asthma. 

  • Learning Objectives

    • Distinguish between asthma control and asthma severity to identify patients with severe asthma based on an understanding of epidemiologic data and ongoing evaluations of symptoms, potential disease phenotypes, and treatment history;
    • Assess the clinical data of newer and emerging cytokine-targeting biologic medications in the treatment of severe asthma;
    • Recognize the benefits of facilitating communication with patients and their caregivers and coordinating with specialists to personalize therapy for patients with severe asthma.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Method of Participation and Receipt of Credit
    In order to receive credit, participants should watch the entire video. Upon completion of the video, please continue to the post-test and evaluation. A passing score of 70% on the post-test is required to receive credit. There is no fee for this activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This program is supported by an educational grant from Genentech, Inc. and AstraZeneca.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/21/20